Fibromyalgia Global Clinical Trials Review, H2, 2017

Pages: 233 Published: August 15, 2017 Report Code: GDHC4477CTIDB

GlobalData's clinical trial report, “Fibromyalgia Global Clinical Trials Review, H2, 2017" provides an overview of Fibromyalgia clinical trials scenario. This report provides top line data relating to the clinical trials on Fibromyalgia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape

– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

– The Report provides enrollment trends for the past five years

– Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Key Players

Pfizer Inc
Eli Lilly and Company
Allergan Plc
Daiichi Sankyo Company Ltd
Tonix Pharmaceuticals Holding Corp
UCB SA
INC Research Holdings Inc
C. H. Boehringer Sohn AG & Co KG
InVentiv Group Holdings
Inc.
Jazz Pharmaceuticals Plc

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Report Guidance 6

GlobalData Clinical Trials Report Coverage 7

Clinical Trials by Region 8

Clinical Trials and Average Enrollment by Country 9

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12

Top Five Countries Contributing to Clinical Trials in Europe 13

Top Countries Contributing to Clinical Trials in North America 14

Top Countries Contributing to Clinical Trials in Middle East and Africa 15

Top Five Countries Contributing to Clinical Trials in Central and South America 16

Clinical Trials by G7 Countries: Proportion of Fibromyalgia to Central Nervous System Clinical Trials 17

Clinical Trials by Phase in G7 Countries 19

Clinical Trials in G7 Countries by Trial Status 20

Clinical Trials by E7 Countries: Proportion of Fibromyalgia to Central Nervous System Clinical Trials 22

Clinical Trials by Phase in E7 Countries 24

Clinical Trials in E7 Countries by Trial Status 25

Clinical Trials by Phase 26

In Progress Trials by Phase 27

Clinical Trials by Trial Status 28

Clinical Trials by End Point Status 30

Subjects Recruited Over a Period of Time 31

Clinical Trials by Sponsor Type 32

Prominent Sponsors 33

Top Companies Participating in Fibromyalgia Therapeutics Clinical Trials 35

Prominent Drugs 37

Latest Clinical Trials News on Fibromyalgia 38

Aug 01, 2017: Aptinyx Initiates Phase 2 Clinical Studies Evaluating NYX-2925 in Two Chronic Pain Conditions 38

Jun 30, 2017: Daiichi Sankyo Announces Top-line Results from Phase 3 Global Clinical Development Program Evaluating Mirogabalin in Pain Syndromes 38

Jun 26, 2017: Zynerba Pharmaceuticals Initiates ZYN001 Phase 1 Clinical Program 39

Clinical Trial Profile Snapshots 40

Appendix 230

Abbreviations 230

Definitions 230

Research Methodology 231

Secondary Research 231

About GlobalData 232

Contact Us 232

Source 233

List of Tables

Fibromyalgia Therapeutics, Global, Clinical Trials by Region, 2017* 8

Fibromyalgia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9

Fibromyalgia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11

Fibromyalgia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 12

Fibromyalgia Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 13

Fibromyalgia Therapeutics Clinical Trials, North America, Top Countries, 2017* 14

Fibromyalgia Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 15

Fibromyalgia Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 16

Proportion of Fibromyalgia to Central Nervous System Clinical Trials, G7 Countries (%), 2017* 17

Fibromyalgia Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19

Fibromyalgia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20

Proportion of Fibromyalgia to Central Nervous System Clinical Trials, E7 Countries (%), 2017* 22

Fibromyalgia Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 24

Fibromyalgia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 25

Fibromyalgia Therapeutics, Global, Clinical Trials by Phase, 2017* 26

Fibromyalgia Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 27

Fibromyalgia Therapeutics, Global, Clinical Trials by Trial Status, 2017* 28

Fibromyalgia Therapeutics Clinical Trials, Global, by End Point Status, 2017* 30

Fibromyalgia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 31

Fibromyalgia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 32

Fibromyalgia Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 33

Fibromyalgia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 35

Fibromyalgia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 37

List of Figures

Fibromyalgia Therapeutics, Global, Clinical Trials by Region (%), 2017* 8

Fibromyalgia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9

Fibromyalgia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11

Fibromyalgia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 12

Fibromyalgia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 13

Fibromyalgia Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 14

Fibromyalgia Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 15

Fibromyalgia Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 16

Proportion of Fibromyalgia to Central Nervous System Clinical Trials, G7 Countries (%), 2017* 17

Fibromyalgia Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19

Fibromyalgia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20

Proportion of Fibromyalgia to Central Nervous System Clinical Trials, E7 Countries (%), 2017* 22

Fibromyalgia Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 24

Fibromyalgia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 25

Fibromyalgia Therapeutics, Global, Clinical Trials by Phase (%), 2017* 26

Fibromyalgia Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 27

Fibromyalgia Therapeutics, Global, Clinical Trials by Trial Status, 2017* 28

Fibromyalgia Therapeutics Clinical Trials, Global, by End Point Status, 2017* 30

Fibromyalgia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 31

Fibromyalgia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 32

Fibromyalgia Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 33

Fibromyalgia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 35

Fibromyalgia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 37

GlobalData Methodology 231

$2,500

Can be used by individual purchaser only

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about our multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.

Still undecided about purchasing this report?

Testimonial

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods